The effect of BCG revaccination on the response to unrelated vaccines in urban Ugandan adolescents (POPVAC C) an open-label, randomised controlled trial

Nassuuna, J.; Zirimenya, L.; Nkurunungi, G.; Natukunda, A.; Zziwa, C.; Ninsiima, C.; ... ; POPVAC trial team (2024)

Article / Letter to editor

Background: Immune responses induced by several important vaccines differ between populations, with reduced responses in low-income and rural settings compared with high-income and urban settings. BCG immunisation boosts immune responses to some unrelated vaccines in high-income populations. We aimed to test the hypothesis that BCG revaccination can enhance responses to unrelated vaccines in Ugandan schoolchildren. Methods: We conducted an open-label, randomised controlled trial to compare the effects of BCG revaccination versus no BCG revaccination on the immunogenicity of subsequent unrelated vaccines among adolescents aged 13-17 years who are participants in an urban Ugandan birth cohort study, in which BCG vaccination was documented at birth. Participants were excluded if they had received any of the trial vaccines or related agents when aged 5 years or older. Computer-generated 1:1 randomisation was implemented in REDCap. Participants were excluded if they were concurrently enrolled in other trials; had a clinically significant history of immunodeficiency, or serious psychiatric conditions or moderate to severe acute illnesses; were taking immunosuppressive medications; had allergies to vaccine components, a predisposition towards developing keloid scarring; positive HIV tests or pregnancy tests; were female participants who were lactating; or if they planned to use investigational drugs, vaccines, blood products, or any combination thereof. Trial participants assigned to the BCG revaccination group received the live parenteral BCGRussia vaccine (Serum Institute of India, Pune, India; 01 mL intradermally, right upper arm) at week 0. All participants received yellow fever vaccine (YF-17D; Sanofi Pasteur, Lyon, France; 05 mL intramuscularly, left upper arm), live oral typhoid vaccine (Ty21a; PaxVax, London, UK; one capsule per day taken for three alternate days), and quadrivalent virus- like particle human papillomavirus (HPV) vaccine (Merck, Rahway, NJ, USA; 05 mL intramuscularly, left upper arm) at week 4; and toxoid vaccines (tetanus-diphtheria; Serum Institute of India; 05 mL intramuscularly, left upper arm) and an HPV booster at week 28. An additional HPV vaccination at week 8 was provided to female participants older than 14 years who had not previously been vaccinated. The primary outcomes were yellow fever neutralising antibody titres at 4 weeks post-YF-17D vaccination, Salmonella enterica serovar Typhi (henceforth S Typhi) O-lipopolysaccharide (O:LPS)-specific IgG concentration at 4 weeks post-Ty21a vaccination, and HPV-16 and HPV-18 L1 protein-specific IgG concentration at 4 weeks post-HPV vaccination. Primary outcome assays were conducted at week 8, and at week 52 for tetanus-diphtheria. We conducted an intention-to-treat analysis comparing log-transformed outcomes between trial groups, with results back-transformed to geometric mean ratios (GMRs). The safety population comprised all randomly allocated participants. The trial was registered at the ISRCTN Registry (ISRCTN10482904) and is complete. Findings: Between Aug 31 and Oct 12, 2020, we screened 376 potential participants for eligibility. We enrolled and randomly allocated 300 participants to the two groups (151 [50%] to the BCG group and 149 [50%] to the no BCG group). 178 (59%) of 300 participants were male and 122 (41%) were female. 142 (91%) of 151 participants in the BCG group and 139 (93%) of 149 in the no BCG group completed follow-up.There was no effect of BCG revaccination, compared with no BCG revaccination, on the response observed for any vaccine. Yellow fever plaque reduction neutralising reference tests (PRNT50) 50 ) titres (the reciprocal of the last plasma dilution that reduced by 50%) had a GMR of 095 (95% CI 075-119; p=062) and PRNT90 90 (reciprocal of the last plasma dilution that reduced by 90%) had a GMR of 094 (074-119; p=060); IgG to S Typhi O:LPS was 099 (080-123; p=094); IgG to HPV-16 was 097 (069-135; p=085) and to HPV-18 was 103 (076-140; p=083); and toxoid-specific IgG for tetanus was 113 (087-147; p=036) and was 100 (087-116; p=097) for diphtheria. There were no serious adverse events in either group. Interpretation: We found no evidence that BCG revaccination is an effective strategy to improve immunogenicity of other vaccines in this low-income, urban setting. Funding: UK Medical Research Council. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

• All authors: Nassuuna, J.; Zirimenya, L.; Nkurunungi, G.; Natukunda, A.; Zziwa, C.; Ninsiima, C.; Apule, B.; Onen, C.; Amongi, S.; Serubanja, J.; Tumwesige, P.; Nsubuga, D.; Amongin, R.; Dam, G.J.V.; Corstjens, P.L.A.M.; Kayiwa, J.; Kabagenyi, J.; Cose, S.; Wajja, A.; Kaleebu, P.; Webb, E.L.; Elliott, A.M.; POPVAC trial team
• Date: 2024-10-16
• Journal: The Lancet Global Health
• Volume: 12
• Issue: 11
• Pages: e1849 - e1859
• DOI: doi:10.1016/S2214-109X(24)00282-1
• Link: https://www.sciencedirect.com/science/article/pii/S2214109X24002821?via%...